ReviewJournal of immunology (Baltimore, Md. : 1950)2018
A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.
Review in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.Cancer medicine · 2023Pooled it
- Exploring the immunological effects of antibody-drug conjugates.Nature reviews. Clinical oncology · 2026Review
- Environmentally induced cell stiffening shapes metastatic site selection by tuning the immune vulnerability of cancer cells.Immunity · 2026Article
- Divergent Prognostic Impact of Histopathological Features and Combined Hematological-Biochemical Indices in Rectal Versus Colorectal Cancer: A Single-Center Study.World journal of oncology · 2026Article
- Identifying and reprogramming softness-driven cancer stem-like cells overcomes CAR-T cell resistance in solid tumours.Nature biomedical engineering · 2026Article
- Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence.Nature biomedical engineering · 2026Article
- A case of dramatic response to pembrolizumab monotherapy in dMMR unresectable colorectal cancer diagnosed following abdominal hemorrhage due to segmental arterial mediolysis.Clinical journal of gastroenterology · 2026Article
- Magnifying Glass on Sinonasal NUT Carcinoma Heterogeneity via Spatial Transcriptomics.Head & neck · 2026Article
- Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment.Nature reviews. Cancer · 2025Review
- Multi-modal single-cell platform for nanoparticle-enhanced time-series metabolic profiles of CD8Journal of nanobiotechnology · 2025Article
- Causality Between Immune Cells, Metabolites and Breast Cancer: Mendelian Randomization and Mediation Analysis.Biochemical genetics · 2025Article
- Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR.British journal of cancer · 2025Article
- Phospholipid-Rich DC-Vesicles with Preserved Immune Fingerprints: A Stable and Scalable Platform for Precision Immunotherapy.Biomedicines · 2025Article
- Mechanoimmunological Control of Metastatic Site Selection.bioRxiv : the preprint server for biology · 2025Article
- Molecular hydrogen as a potential mediator of the antitumor effect of inulin consumption.Scientific reports · 2025Article
- Metabolic Reprogramming of Anti-cancer T Cells: Targeting AMPK and PPAR to Optimize Cancer Immunotherapy.Indian journal of clinical biochemistry : IJCB · 2025Review
- PredLyP: A computational tool for predicting tissue-specific (phago-)lysosomal post-digestion peptides.Computational and structural biotechnology journal · 2025Article
- A Comprehensive Review on Novel Therapies for Gastrointestinal Cancers using Translational Platforms.Current pharmaceutical design · 2025Review
- Fisetin reduces the resistance of MOLT-4 and K562 cells to TRAIL-induced apoptosis through upregulation of TRAIL receptors.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- DNA methylation analysis of peripheral blood mononuclear cells in diagnosing breast cancer from benign breast lesions.Journal of translational medicine · 2024Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The field of tumor immunology has grown around the idea that one of the important roles of the immune system is to eliminate cancer. This idea was difficult to reconcile with the accepted notion that the immune system evolved to distinguish self from nonself and therefore tumors derived from self-tissues would not be recognized. Lack of appropriate animal models prevented experimental testing of cancer immunosurveillance. This changed with the realization that the immune system evolved to recognize danger and with the advent of mouse models deficient in one or more immune function, which showed predicted increases in susceptibility to cancer. Simultaneously, technical advances that enabled the study of the human immune system provided data for the existence of tumor-specific T cells and Abs and led to molecular identification of tumor Ags, fully validating the cancer immunosurveillance hypothesis. Immunotherapy designed to strengthen cancer immunosurveillance has achieved unprecedented clinical successes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.